Goodrx Holdings Stock Alpha and Beta Analysis
| GDRX Stock | USD 4.42 0.05 1.12% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Goodrx Holdings. It also helps investors analyze the systematic and unsystematic risks associated with investing in Goodrx Holdings over a specified time horizon. Remember, high Goodrx Holdings' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Goodrx Holdings' market risk premium analysis include:
Beta 1.17 | Alpha 0.0572 | Risk 2.91 | Sharpe Ratio (0.01) | Expected Return (0.02) |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Goodrx |
Goodrx Holdings Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Goodrx Holdings market risk premium is the additional return an investor will receive from holding Goodrx Holdings long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Goodrx Holdings. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Goodrx Holdings' performance over market.| α | 0.06 | β | 1.17 |
Goodrx Holdings expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Goodrx Holdings' Buy-and-hold return. Our buy-and-hold chart shows how Goodrx Holdings performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Goodrx Holdings Market Price Analysis
Market price analysis indicators help investors to evaluate how Goodrx Holdings stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Goodrx Holdings shares will generate the highest return on investment. By understating and applying Goodrx Holdings stock market price indicators, traders can identify Goodrx Holdings position entry and exit signals to maximize returns.
Goodrx Holdings Return and Market Media
The median price of Goodrx Holdings for the period between Sun, Dec 15, 2024 and Sat, Mar 15, 2025 is 4.71 with a coefficient of variation of 4.76. The daily time series for the period is distributed with a sample standard deviation of 0.22, arithmetic mean of 4.71, and mean deviation of 0.19. The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | Disposition of 23150 shares by Kennedy Kelly J. of Goodrx Holdings subject to Rule 16b-3 | 12/20/2024 |
2 | Acquisition by Bruehlman Ronald E of 10653 shares of Goodrx Holdings subject to Rule 16b-3 | 12/31/2024 |
3 | Disposition of 89292 shares by Karsten Voermann of Goodrx Holdings subject to Rule 16b-3 | 01/08/2025 |
4 | Disposition of 2606 shares by Romin Nabiey of Goodrx Holdings subject to Rule 16b-3 | 01/15/2025 |
5 | Acquisition by Scott Wagner of 94182 shares of Goodrx Holdings subject to Rule 16b-3 | 01/21/2025 |
6 | Insider Trading | 02/04/2025 |
7 | Disposition of 5202 shares by Romin Nabiey of Goodrx Holdings at 4.84 subject to Rule 16b-3 | 02/07/2025 |
8 | GoodRx Holdings, Inc. Given Consensus Recommendation of Moderate Buy by Analysts - MarketBeat | 02/12/2025 |
9 | GoodRx Achieves HITRUST i1 Certification to Manage Data Protection and Mitigate Cybersecurity Threats | 02/18/2025 |
10 | Insights Into GoodRx Q4 Wall Street Projections for Key Metrics | 02/25/2025 |
11 | GoodRx Holdings Inc Q4 2024 Everything You Need To Know Ahead Of Earnings | 02/26/2025 |
12 | GoodRx Misses Q4 Revenue Estimates | 02/27/2025 |
13 | Q4 2024 GoodRx Holdings Inc Earnings Call Transcript | 02/28/2025 |
14 | Acquisition by Wendy Barnes of 409416 shares of Goodrx Holdings subject to Rule 16b-3 | 03/03/2025 |
15 | Balanced Outlook on GoodRx Holdings Growth Potential Amidst Cautious Market Expectations - TipRanks | 03/04/2025 |
16 | Acquisition by Romin Nabiey of 76866 shares of Goodrx Holdings subject to Rule 16b-3 | 03/05/2025 |
17 | Disposition of 2233 shares by Romin Nabiey of Goodrx Holdings subject to Rule 16b-3 | 03/07/2025 |
18 | GoodRx Report Reveals Striking Gender Divide in Prescription Medication Spending | 03/10/2025 |
About Goodrx Holdings Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Goodrx or other stocks. Alpha measures the amount that position in Goodrx Holdings has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2024 | 2025 (projected) | Dividend Yield | 0.0674 | 0.0599 | Price To Sales Ratio | 2.26 | 2.15 |
Goodrx Holdings Upcoming Company Events
As portrayed in its financial statements, the presentation of Goodrx Holdings' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Goodrx Holdings' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Goodrx Holdings' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Goodrx Holdings. Please utilize our Beneish M Score to check the likelihood of Goodrx Holdings' management manipulating its earnings.
| 27th of February 2024 Upcoming Quarterly Report | View | |
| 8th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 27th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Goodrx Holdings
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Additional Tools for Goodrx Stock Analysis
When running Goodrx Holdings' price analysis, check to measure Goodrx Holdings' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Goodrx Holdings is operating at the current time. Most of Goodrx Holdings' value examination focuses on studying past and present price action to predict the probability of Goodrx Holdings' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Goodrx Holdings' price. Additionally, you may evaluate how the addition of Goodrx Holdings to your portfolios can decrease your overall portfolio volatility.